- Home
- TAC vs AAPG Comparison
TAC vs AAPG Comparison
Compare TAC & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- AAPG
- Stock Information
- Founded
- TAC 1909
- AAPG 2009
- Country
- TAC Canada
- AAPG China
- Employees
- TAC N/A
- AAPG N/A
- Industry
- TAC Electric Utilities: Central
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- TAC Utilities
- AAPG Health Care
- Exchange
- TAC Nasdaq
- AAPG Nasdaq
- Market Cap
- TAC 2.7B
- AAPG 2.2B
- IPO Year
- TAC N/A
- AAPG 2025
- Fundamental
- Price
- TAC $9.76
- AAPG $24.40
- Analyst Decision
- TAC Buy
- AAPG Buy
- Analyst Count
- TAC 2
- AAPG 1
- Target Price
- TAC $19.75
- AAPG N/A
- AVG Volume (30 Days)
- TAC 1.3M
- AAPG 14.1K
- Earning Date
- TAC 05-07-2025
- AAPG 06-10-2025
- Dividend Yield
- TAC 1.79%
- AAPG N/A
- EPS Growth
- TAC N/A
- AAPG N/A
- EPS
- TAC 0.00
- AAPG N/A
- Revenue
- TAC $1,847,844,992.00
- AAPG $134,352,180.00
- Revenue This Year
- TAC N/A
- AAPG N/A
- Revenue Next Year
- TAC N/A
- AAPG $389.09
- P/E Ratio
- TAC $4,153.91
- AAPG N/A
- Revenue Growth
- TAC N/A
- AAPG 341.77
- 52 Week Low
- TAC $6.78
- AAPG $16.50
- 52 Week High
- TAC $14.64
- AAPG $26.55
- Technical
- Relative Strength Index (RSI)
- TAC 63.93
- AAPG N/A
- Support Level
- TAC $8.73
- AAPG N/A
- Resistance Level
- TAC $9.20
- AAPG N/A
- Average True Range (ATR)
- TAC 0.26
- AAPG 0.00
- MACD
- TAC 0.10
- AAPG 0.00
- Stochastic Oscillator
- TAC 91.96
- AAPG 0.00
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.